Monoclonal Gammopathy of Undetermined Significance (MGUS) Management Market

Future Market Insights

Key Insight

The monoclonal gammopathy of undetermined significance (mgus) management market is projected to grow from USD 30.9 billion in 2025 to USD 60.8 billion by 2035, at a CAGR of 7.0%. Alendronate will dominate with a 48.7% market share, while hospital pharmacies will lead the distribution channel segment with a 42.9% share.

September 04, 2025

Anurag Sharma

299 Pages

Cite this Report

Monoclonal Gammopathy of Undetermined Significance (MGUS) Management Market

https://www.futuremarketinsights.com/reports/mgus-management-market

License

Buy Now

Summary ToC Companies

Key Players

Array Biopharma Inc
Hoffmann-La Roche Ltd
Merck KGaA
Omega Diagnostics Group PLC
PhaseBio Pharmaceuticals Inc
Sanofi-Aventis US LLC
Siemens Healthcare GmbH

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Monoclonal Gammopathy of Undetermined Significance (MGUS) Management Market

Key Players

Similar Industry Reports